Dexmedetomidine in Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy

NCT ID: NCT02031510

Last Updated: 2015-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 195 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2015-03-31

Brief Summary

The use of dexmedetomidine as an adjunct to bupivacaine in transversus abdominis plane block will reduce the cumulative morphine consumption after laparoscopic cholecystectomy.

Detailed Description

Laparoscopic cholecystectomy, which is a common surgical procedure, is associated with less postoperative pain in comparison to open cholecystectomy. However, this pain needs to be treated adequately to allow early mobilization.

Ultrasound guided transversus abdominis plane (TAP) block is an established technique to manage post laparoscopic cholecystectomy pain. 1 In addition, the use of TAP blocks reduced the need for intraoperative and postoperative opioids and the side-effects associated with their use.

The aim of a TAP block is to deposit local anaesthetic in the plane between the internal oblique and transversus abdominis muscles targeting the spinal nerves in this plane. The innervation to abdominal skin, muscles and parietal peritoneum will be interrupted.

Dexmedetomidine which is an Alpha 2-adrenergic agonist produces analgesia via a non-opioid mechanism and is also known to enhance central and peripheral neural blockades.2 Dexmedetomidine added to bupivacaine or levobupivacaine for brachial plexus block shortens sensory and motor block onset time, extends motor and sensory block durations, and also extends the postoperative analgesia.3, 4

We postulate that the use of dexmedetomidine as an adjunct to bupivacaine in transversus abdominis plane block will reduce the morphine consumption after laparoscopic cholecystectomy.

Based upon previous published data,4 a priori power analysis indicated that 60 patients in each group would be sufficient to detect a 30% reduction in the 24-hours cumulative morphine consumption, which is considered to be of clinical validity, with a type-I error of 0.0167 (0.05/4) and a power of 80%. We added 10% extra patients to compensate for possible dropouts.

All patients will be familiarized with a 10-cm visual analogue scale (VAS) (0= no pain; 10= worst imaginable) to assess the intensity of pain and on the use of the patient-controlled analgesia (PCA).

Monitoring includes non-invasive blood pressure, and electrocardiography, pulse oximetry.

An intravenous infusion of 10 ml kg-1 of Lactated Ringer's solution will be initiated before surgery and will be followed by 5 ml kg-1 hr-1 throughout the procedure.

Anaesthesia technique will be standardized. Anesthesia will be induced by fentanyl of 2-3 µg kg-1, propofol 1.5-2.5 mg kg-1, and rocuronium 0.6 mg kg-1. Tracheal intubation will be carried out at the development of maximum block as monitored by the train-of-four (TOF).

Anesthesia, consisting of a 0.7-1.5 minimum alveolar concentration (MAC) of sevoflurane, will be administered to maintain heart rate (HR) and mean arterial blood pressure (MAP) values below 20% of baseline values. Fentanyl 0.5μg/kg increments will be administered when the HR and MAP values are > 20% of baseline values, despite a target sevoflurane of MAC ≥ 1.5. When the HR and MAP values < 20% of baseline values, the sevoflurane MAC is decreased gradually to 0.7 MAC.

Patients' lungs will be ventilated to achieve a PaCO2 of 35-45 mm Hg. All patients will receive intravenous granisetron 1 mg and lornoxicam 16 mg after the induction of anaesthesia. Rocuronium increments will be given to maintain suppression of the second twitch in the TOF.

The anaesthesiologists who will perform the TAP block and give the anaesthetics will not be involved in the patients' assessment. All other staff in the operating room is unaware of the randomization code.

The TAP block will be performed using ultrasound (SonoSite M-Turbo®, Sonosite, USA) guidance as described by Ra et al

All operations will be performed by the same surgeons. CO2 pneumoperitoneum will be introduced and intra-abdominal insufflation pressure will be limited to 12 mm Hg. After introducing of the four trocars, the patient will be placed in the reverse Trendelenburg position, using up to 30° of head-up tilt. No supplementary dose of muscle relaxant was administered 30 minutes before the end of the surgery.

After desufflation of CO2 pneumoperitoneum, the patient will be returned to the horizontal position and during skin closure; neuromuscular blockade will be antagonized with 50 µg kg-1 neostigmine and 10 µg kg-1 glycopyrrolate. At the last skin suture, desflurane will be discontinued and tracheal extubation will be performed at the discretion of the involved anesthetist in the patient's management.

A standard postoperative analgesic regimen, consisting of 12-hourly intravenous lornoxicam 8 mg, 6-hourly intravenous paracetamol 1 g and intravenous morphine PCA (incremental dose, 1 mg; lockout time, 6-min; a maximum 4-hourly limit, 30 mg), will be used in all patients. If the patient has persistent postoperative nausea and/or vomiting, metoclopramide 10 mg will be administered intravenously when needed.

Other independent investigators who will be blinded to the study protocol and the patient's randomization code will collect the patient's data.

Conditions

Elective Laparoscopic Cholecystectomy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

bupivacaine-dexmedetomidine

transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1

Group Type: ACTIVE_COMPARATOR

bupivacaine-dexmedetomidine

Intervention Type: DRUG

transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1

bupivacaine

transversus abdominis plane block with bupivacaine 0.25%

Group Type: ACTIVE_COMPARATOR

bupivacaine

Intervention Type: DRUG

transversus abdominis plane block bupivacaine 0.25%

placebo

Transversus abdominis block with saline 0.9%

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

transversus abdominis plane block with saline 0.9%

Interventions

placebo

transversus abdominis plane block with saline 0.9%

Intervention Type: DRUG

bupivacaine

transversus abdominis plane block bupivacaine 0.25%

Intervention Type: DRUG

bupivacaine-dexmedetomidine

transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• American Society of Anesthesiologists class I and II patients
• general anaesthesia

Exclusion Criteria

• cardiovascular disease
• respiratory disease
• neurological disease
• renal disease
• hepatic disease
• hormonal disease
• pregnancy
• body mass index > 35 kg/m2)
• smokers
• alcohol abuse
• use of antipsychotics
• communication barriers
• local anesthetics allergy
• chronic use of opioids
• use of nonsteroidal anti-inflammatory drug use during the 24 hours immediately preceding surgery
• coagulation disorders
• infection at the needle insertion
• conversion of laparoscopic to open cholecystectomy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mansoura University

OTHER

Sponsor Role: collaborator

Imam Abdulrahman Bin Faisal University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Abdulmohsen A Al Ghamdi, MD

Role: PRINCIPAL_INVESTIGATOR

Chairman of Anesthesiology Dept

Locations

King Fahd Hospital of Dammam University

Khobar, Eastern Province, Saudi Arabia

Dammam University

Khobar, Eastern Province, Saudi Arabia

Countries

Saudi Arabia

Other Identifiers

Anesth-Nov13(2)

Identifier Type: -

Identifier Source: org_study_id